|
Characteristics of included patients |
|
| Characteristics |
|
|
|
|
| Number of patients |
24 |
| Liver Disease |
|
| HCV |
19 (79%) |
| HCV-HIV |
2 (8%) |
| Alcohol |
3 (13%) |
| Duration of liver disease (years) – mean (sd) |
21 (4) |
| Age at biopsy (years) – mean (sd) |
49 (11) |
| Age at serum sample (years) – mean (sd) |
52 (11) |
| Duration between biopsy and serum sample (years) – mean (sd) |
2.7 (1.4) |
| Male (%) |
16 (67%) |
| Female (%) |
8 (33%) |
| Mode of HCV infection |
|
| Transfusion (%) |
6 (29%) |
| IV drug use |
9 (42%) |
| Unknown |
6 (29%) |
| HCV Genotype |
|
| 3 |
1 (5%) |
| 1 |
20 (95%) |
| Baseline viral load (median in million IU/ml) |
5 |
| Fibrosis stage (unknown in 2) |
|
| No fibrosis (F0) |
1 (5%) |
| Portal fibrosis or (F1) |
8 (36%) |
| Few septa (F2) |
7 (32%) |
| Many septa (F3) |
0 (0%) |
| Cirrhosis (F4) |
6 (27%) |
| Activity grade (unknown in 2) |
|
| None (A0) |
2 (10%) |
| Mild (A1) |
15 (67%) |
| Moderate (A2) |
5 (23%) |
| Severe (A3) |
0 (0%) |
| Biopsy size (median in mm) |
17 |
| Status of patients (response to treatment) |
|
| Sustained responder |
4 (19%) |
| Relapser |
1 (5%) |
| Non responder |
10 (48%) |
| Not treated |
6 (28%) |
|
HCV – hepatitis C virus; HIV – human immunodeficiency virus; sd – standard deviation. | |
Halfon et al. Comparative Hepatology 2002 1:3 doi:10.1186/1476-5926-1-3 |
|